EUVIMEDEUVIMED entdecken
Crossref

Modifiable statin characteristics associated with potential statin‐related prescribing cascades

Grace Hsin-Min Wang iD, Earl Morris iD, Scott M Vouri iD, Shailina Keshwani iD, Stephan Schmidt, Carl J Pepine iD, Steven M Smith iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023

DOI: 10.1002/phar.2883 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023. Verfasst von Grace Hsin-Min Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: UF College of Pharmacy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study Objective Clinicians may prescribe new medications (marker drug) to treat statin‐related (index drug) adverse events, constituting a prescribing cascade. We aimed to identify modifiable statin characteristics (intensity and individual statin agents) associated with lower risk of prescribing cascades to inform clinical decisions in the presence of statin‐related adverse events.

Design

A secondary analysis based on our previous work, a high‐throughput sequence symmetry analysis screening for potential statin‐related prescribing cascades. Data Source MarketScan Commercial and Medicare Supplemental Insurance claims databases between 2005 and 2019. Patients Adults who initiated a statin between 2007 and 2018, and who were continuously enrolled in the same healthcare plan for at least 720 days before and 360 days after statin initiation.

Intervention

Among the previously identified 57 potential prescribing cascades, 42 statin‐marker class dyad with a sample size of ≥ 500 were assessed in this study.

Measurements

We measured patients’ baseline characteristics within −360 days of statin initiation and reported by modifiable statin characteristics. We also performed logistic regression and reported the adjusted odds ratios (aOR) with 95% confidence intervals (CI) of modifiable statin characteristics after adjusting for baseline characteristics. Main Results We identified 1,307,867 statin initiators who met the study criteria (21% elderly, 52% female). Compared with patients initiating low‐intensity statins, those initiating moderate‐ or high‐intensity statins had significantly greater odds to develop 29 (69%) prescribing cascades, including antidiabetic drugs such as dipeptidyl peptidase 4 (DPP‐4) inhibitors (aOR 1.22; 95% CI, 1.11–1.35) and glucagon‐like peptide‐1 (GLP‐1) analogs (aOR 1.31; 95% CI, 1.16–1.47), and opioids (aOR 1.18; 95% CI, 1.13–1.23). Individual statin agent selection also had a differential effect on 34 (81%) of the prescribing cascades. For example, compared with simvastatin initiators, the probability of initiating osmotically acting laxatives was significantly higher for lovastatin initiators (aOR 1.09; 95% CI, 1.03–1.15) and significantly lower in atorvastatin initiators (aOR 0.92; 95% CI, 0.89–0.94).

Conclusion

Compared with low‐intensity statins, high‐intensity statins are associated with increased risk in many potential prescribing cascades, while the choice of individual statin agents affects the risk of prescribing cascades bidirectionally.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsDipeptidyl-Peptidase IV InhibitorsAdultHumansFemaleAgedUnited StatesMaleMedicareAtorvastatinSimvastatinLovastatinRetrospective Studies

Stichwörter der Autor:innen

drug prescriptionsdrug-related side effects and adverse reactionshydroxymethylglutaryl-CoA reductase inhibitors

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsAtorvastatinSimvastatinLovastatinDipeptidyl-Peptidase IV Inhibitors

Autor:innen und Institutionen

  • Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, Florida, USA.
  • Center for Drug Evaluation and Safety, University of Florida, Gainesville, Florida, USA.
  • Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA.
  • Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
  • Center for Integrative Cardiovascular and Metabolic Disease, University of Florida, Gainesville, Florida, USA.

ORCID-Profile: Grace Hsin-Min Wang, Earl Morris, Scott M Vouri, Shailina Keshwani, Carl J Pepine, Steven M Smith

Förderung

  • UF College of Pharmacy

Zitieren

APA

Wang, G. H., Morris, E., Vouri, S. M., Keshwani, S., Schmidt, S., Pepine, C. J., & Smith, S. M. (2023). Modifiable statin characteristics associated with potential statin‐related prescribing cascades. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2883

Vancouver

Wang GH, Morris E, Vouri SM, Keshwani S, Schmidt S, Pepine CJ, et al. Modifiable statin characteristics associated with potential statin‐related prescribing cascades. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023. doi:10.1002/phar.2883

BibTeX
@article{Wang2023,
  author = {Wang, Grace Hsin-Min and Morris, Earl and Vouri, Scott M and Keshwani, Shailina and Schmidt, Stephan and Pepine, Carl J and Smith, Steven M},
  title = {Modifiable statin characteristics associated with potential statin‐related prescribing cascades},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2023},
  doi = {10.1002/phar.2883}
}
Kostenlos starten →